BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 26860959)

  • 21. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
    Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
    Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
    Ohka F; Ito M; Ranjit M; Senga T; Motomura A; Motomura K; Saito K; Kato K; Kato Y; Wakabayashi T; Soga T; Natsume A
    Tumour Biol; 2014 Jun; 35(6):5911-20. PubMed ID: 24590270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long noncoding RNA papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3) inhibits proliferation and invasion of glioma cells by suppressing the Wnt/β-catenin signaling pathway.
    Xia S; Ji R; Zhan W
    BMC Neurol; 2017 Feb; 17(1):30. PubMed ID: 28187755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The expression of IDH1 (R132H) is positively correlated with cell proliferation and angiogenesis in glioma samples].
    Shi J; Zhao Y; Yuan Y; Wang C; Xie Z; Gao X; Xiao L; Ye J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Mar; 32(3):360-3. PubMed ID: 26927556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IDH1 mutation activates mTOR signaling pathway, promotes cell proliferation and invasion in glioma cells.
    Avsar T; Kose TB; Oksal MD; Turan G; Kilic T
    Mol Biol Rep; 2022 Oct; 49(10):9241-9249. PubMed ID: 35934766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
    Xu Q; Ahmed AK; Zhu Y; Wang K; Lv S; Li Y; Jiang Y
    Biochem Biophys Res Commun; 2018 May; 499(4):882-888. PubMed ID: 29625108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas.
    Cai J; Zhu P; Zhang C; Li Q; Wang Z; Li G; Wang G; Yang P; Li J; Han B; Jiang C; Sun Y; Jiang T
    Oncotarget; 2016 Mar; 7(13):16384-95. PubMed ID: 26918938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence.
    Zhan D; Ma D; Wei S; Lal B; Fu Y; Eberhart C; Laterra J; Ying M; Li Y; Meeker A; Lopez-Bertoni H; Xia S
    Mol Cancer Res; 2021 Nov; 19(11):1878-1888. PubMed ID: 34348994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reprogramming the immunosuppressive microenvironment of IDH1 wild-type glioblastoma by blocking Wnt signaling between microglia and cancer cells.
    Fan D; Yue Q; Chen J; Wang C; Yu R; Jin Z; Yin S; Wang Q; Chen L; Liao X; Peng C; Zhang J; Cao Z; Mao Y; Huang R; Chen L; Li C
    Oncoimmunology; 2021 Jun; 10(1):1932061. PubMed ID: 34123575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH1 gene mutation activates Smad signaling molecules to regulate the expression levels of cell cycle and biological rhythm genes in human glioma U87‑MG cells.
    Gao Y; Wu Y; Zhang N; Yuan H; Wang F; Xu H; Yu J; Ma J; Hou S; Cao X
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
    Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
    Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1
    Kondo N; Barth RF; Miyatake SI; Kawabata S; Suzuki M; Ono K; Lehman NL
    J Neurooncol; 2017 May; 133(1):107-118. PubMed ID: 28534152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IDH1
    Han X; Zhou H; Sun W; Hou L; Wang Y; Wang H; Lv Z; Xue X
    Sci Rep; 2023 Nov; 13(1):19659. PubMed ID: 37952042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.
    Sabit H; Nakada M; Furuta T; Watanabe T; Hayashi Y; Sato H; Kato Y; Hamada J
    Brain Tumor Pathol; 2014 Oct; 31(4):242-6. PubMed ID: 24384677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens.
    Preusser M; Wöhrer A; Stary S; Höftberger R; Streubel B; Hainfellner JA
    J Neuropathol Exp Neurol; 2011 Aug; 70(8):715-23. PubMed ID: 21760534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
    Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ
    Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PAX3 Promotes Proliferation of Human Glioma Cells by WNT/β-Catenin Signaling Pathways.
    Liang X; Dong Z; Bin W; Dekang N; Xuhang Z; Shuyuan Z; Liwen L; Kai J; Caixing S
    J Mol Neurosci; 2019 May; 68(1):66-77. PubMed ID: 30826985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isocitrate Dehydrogenase 1 Expression in Canine Gliomas.
    Fraser AR; Bacci B; le Chevoir MA; Long SN
    J Comp Pathol; 2018 Nov; 165():33-39. PubMed ID: 30502793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. cMYC expression in infiltrating gliomas: associations with IDH1 mutations, clinicopathologic features and outcome.
    Odia Y; Orr BA; Bell WR; Eberhart CG; Rodriguez FJ
    J Neurooncol; 2013 Nov; 115(2):249-59. PubMed ID: 23934175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MAGI3 negatively regulates Wnt/β-catenin signaling and suppresses malignant phenotypes of glioma cells.
    Ma Q; Yang Y; Feng D; Zheng S; Meng R; Fa P; Zhao C; Liu H; Song R; Tao T; Yang L; Dai J; Wang S; Jiang WG; He J
    Oncotarget; 2015 Nov; 6(34):35851-65. PubMed ID: 26452219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.